Transasia – Erba Group sets a new benchmark in the Indian IVD industry

Transasia Bio-Medicals announced that it has successfully sold over 1,000 units of the recently launched Erba hematology range of analyzers in India, thereby retaining its No. 1 position in the Indian hematology market. Transasia is one of India’s leading In-vitro Diagnostic Industry and a part of the global Transasia-Erba group.

A result of in-depth research and development at the group’s European centre, the Erba hematology range was launched in India just four and half months ago to mark Transasia’s 40th anniversary. The 3-Part (H 360) and 5- Part (H 560 and ELite 580) fully automated hematology analyzers, reagents and controls include a number of features to help institutions, clinicians and laboratory technologists offer accurate diagnosis.

When asked what he felt about this remarkable feat, Suresh Vazirani, Chairman and Managing Director said, “All along the 40 years of our journey, we have been committed to offering the highest level of quality and service to Doctors and their patients. India’s greatest need is the easy access to affordable healthcare. And that is the lacunae that we have been striving to fill by pooling in our best technologies from our global subsidiaries and making them available at affordable prices for Indian hospitals and labs.”

“Our Erba range of hematology analyzers is comparable to the best in the world and is widely used in the European market. I am grateful to our customers for their overwhelming response and our success is an outcome of the trust they bestow in us”, he further added.

Erba H 360 is a 3-Part Differential Hematology analyzer and is suitable for obtaining a complete blood count (CBC) with a three-part differential white blood cell (WBC) count.